FATE Q1 2018 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-0.1% YoY

Gross Profit

-$10M-1018.5% margin

Operating Income

-$14M-1369.8% margin

Net Income

-$14M-1377.7% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-0.1%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$93M

Total Liabilities

$28M

Stockholders' Equity

$65M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	-0.1%
Gross Profit	-$10M	-$7M	-50.6%
Operating Income	-$14M	-$10M	-40.9%
Net Income	-$14M	-$10M	-39.6%